| Pharmacokinetics and pharmacological properties of chloroquine and hydroxychloroquine in the context of COVID‐19 infection MR Nicol, A Joshi, ML Rizk, PE Sabato, RM Savic, D Wesche, JH Zheng, ... Clinical Pharmacology & Therapeutics 108 (6), 1135-1149, 2020 | 42 | 2020 |
| Quantification of dermal and transdermal delivery of meloxicam gels in rabbits M Patel, A Joshi, H Hassanzadeth, R Juluru, G Stagni Drug Development and Industrial Pharmacy 37 (5), 613-617, 2011 | 26 | 2011 |
| Effect of microporation on passive and iontophoretic delivery of diclofenac sodium H Patel, A Joshi, A Joshi, G Stagni Drug Development and Industrial Pharmacy 41 (12), 1962-1967, 2015 | 18 | 2015 |
| FDA public workshop summary: Advancing animal models for antibacterial drug development JM Byrne, U Waack, EA Weinstein, A Joshi, SM Shurland, D Iarikov, ... Antimicrobial Agents and Chemotherapy 65 (1), 10.1128/aac. 01983-20, 2020 | 16 | 2020 |
| Cutaneous penetration–enhancing effect of menthol: calcium involvement A Joshi, A Joshi, H Patel, D Ponnoth, G Stagni Journal of Pharmaceutical Sciences 106 (7), 1923-1932, 2017 | 14 | 2017 |
| Iontophoresis successfully delivers dexamethasone sodium phosphate to dermis as measured by microdialysis A Joshi, G Stagni, A Cleary, K Patel, DS Weiss, M Hagins Journal of Pharmaceutical Sciences 103 (1), 191-196, 2014 | 11 | 2014 |
| Transdermal delivery of etoposide phosphate II: in vitro in vivo correlations (IVIVC) H Patel, A Joshi, A Joshi, G Stagni Journal of Pharmaceutical Sciences 105 (7), 2139-2145, 2016 | 10 | 2016 |
| Transdermal delivery of etoposide phosphate I: in vitro and in vivo evaluation H Patel, A Joshi, A Joshi, G Stagni Journal of Pharmaceutical Sciences 105 (7), 2114-2122, 2016 | 7 | 2016 |
| Pharmacokinetic applications of cutaneous microdialysis: Continuous+ intermittent vs continuous-only sampling A Joshi, H Patel, A Joshi, G Stagni Journal of Pharmacological and Toxicological Methods 83, 16-20, 2017 | 5 | 2017 |
| Regulatory Considerations in the Approval of Rezafungin (Rezzayo) for the Treatment of Candidemia and Invasive Candidiasis in Adults HL Smith, TJ Bensman, S Mishra, X Li, CA Dixon, J Sheikh, OG McMaster, ... The Journal of Infectious Diseases, jiae146, 2024 | 1 | 2024 |
| Variations in pharmacokinetic-pharmacodynamic target values across MICs and their potential impact on determination of susceptibility test interpretive criteria U Waack, A Joshi, SH Jang, KS Reynolds Journal of Antimicrobial Chemotherapy 76 (11), 2884-2889, 2021 | 1 | 2021 |
| Do differences in cell lines and methods used for calculation of IC50 values influence categorisation of drugs as P-glycoprotein substrates and inhibitors? DA Volpe, A Joshi, V Arya Xenobiotica 52 (7), 751-757, 2022 | | 2022 |
| DO DIFFERENCES BETWEEN CELL LINES AND IC50 COMPUTATION METHODS IMPACT THE PREDICTION PERFORMANCE OF CRITERION USED TO PREDICT P-GLYCOPROTEIN (P-GP) INHIBITION POTENTIAL?. A Joshi, DA Volpe, V Arya CLINICAL PHARMACOLOGY & THERAPEUTICS 105, S84-S84, 2019 | | 2019 |
| APPROACHES TO DETERMINE PK/PD TARGET OF beta-LACTAMASE INHIBITORS DURING THE DEVELOPMENT OF beta-LACTAM/beta-LACTAMASE INHIBITOR ANTI-BACTERIAL COMBINATION PRODUCTS. X Wei, A Joshi, K Wu, A Somani, J Moore, S Pahwa, Z Yan, SH Jang CLINICAL PHARMACOLOGY & THERAPEUTICS 103, S92-S92, 2018 | | 2018 |
| Estimation of Systemic Pharmacokinetic Parameters with a Combination of Cutaneous Microdialysis and Sparse Plasma Sampling A Joshi Long Island University, The Brooklyn Center, 2015 | | 2015 |
